Stryker Corporation $SYK Shares Acquired by Davidson Capital Management Inc.

Davidson Capital Management Inc. increased its stake in shares of Stryker Corporation (NYSE:SYK) by 2.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,731 shares of the medical technology company’s stock after purchasing an additional 168 shares during the period. Stryker accounts for about 0.8% of Davidson Capital Management Inc.’s holdings, making the stock its 27th biggest position. Davidson Capital Management Inc.’s holdings in Stryker were worth $3,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. acquired a new position in Stryker in the 2nd quarter valued at about $26,000. Sachetta LLC raised its position in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Ridgewood Investments LLC lifted its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares during the period. Ransom Advisory Ltd acquired a new stake in Stryker during the first quarter worth approximately $37,000. Finally, Solstein Capital LLC purchased a new stake in Stryker in the 2nd quarter worth approximately $43,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price target on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Barclays increased their target price on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Needham & Company LLC lifted their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Finally, Weiss Ratings downgraded shares of Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. Thirteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $433.37.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 520,500 shares of company stock worth $184,803,065 in the last quarter. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.3%

NYSE SYK opened at $355.03 on Tuesday. The company’s 50 day moving average price is $373.91 and its 200 day moving average price is $381.34. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market capitalization of $135.77 billion, a price-to-earnings ratio of 47.02, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.